tert-Butyl 4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine-1-carboxylate

Intermediate for Venetoclax. Venetoclax (trade name Venclexta) is a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality. Venetoclax is a BH3-mimetic and acts as a Bcl-2 inhibitor. Venetoclax has been approved by US FDA om April 11, 2016.

Specifications

Product Name:                  tert-Butyl 4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine-1-carboxylate

Synonyms:                         N/A

CAS Number:                     1228780-71-9

Molecular Weight:            419.0057

Molecular Formula:          C24H35ClN2O2

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               ClC1=CC=C(C2=C(CN3CCN(C(OC(C)(C)C)=O)CC3)CCC(C)(C)C2)C=C1

tert-Butyl 4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine-1-carboxylate

  • $800.00
  • Ex Tax: $800.00

Available Options